Streptococci Testing Market
Number of pages: 100 | Report Format: PDF | Published date: April 04, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
CAGR |
3.2% |
|
Base Year For Estimation |
2022 |
|
Forecast Period |
2023-2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Test Type, End User, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global Streptococci testing market is expected to register a revenue CAGR of 3.2% by 2031.
Streptococci Testing Market Fundamentals
Streptococci are spherical organisms that develop in chains due to imperfect cell separation after mitosis. Streptococci were originally categorized according to the illness they produced; however, because of advancements in diagnostics and the availability of modern molecular methods, many shifts in the taxonomy of the Streptococcus genus have occurred in the last decade. Historically, a helpful distinguishing feature of streptococci has been their response to blood agar, caused by the lysis of erythrocytes by Streptococcus enzymes - a process known as hemolysis.
Streptococci were separated into -hemolytic and non-hemolytic families based on this trait. Streptococci were categorized further in 1934 based on group-specific polysaccharides on the bacterium surface. The majority of -hemolytic streptococci have been investigated in this serogrouping. So far, thirteen distinct serological groups have been discovered, with groups A, B, C, and G, Streptococcus pneumoniae, and viridans group streptococci most essential for human health.
Streptococcus species are non-pneumococcal gram-positive streptococci. There are now roughly 50 Streptococci species, but only five induce illness in people. Group A contains beta-hemolytic S. pyogenes; Group B contains beta-hemolytic S. agalactiae; Group C contains beta-hemolytic S. agalactiae; Group D contains Enterococcus; and Group F has alpha-hemolytic S. viridans. These account for about 1% of adult pneumonia, mostly caused by Group A, beta-hemolytic streptococcus. Group B streptococci commonly cause neonatal pneumonia.
Cultures from clinical specimens are used to make the diagnosis. Serologic techniques can identify group A or B antigens; the precipitin test is the ultimate antigen identification procedure. Bacitracin sensitivity distinguishes group A from other -hemolytic streptococci (B, C, G); group B streptococci usually exhibit hippurate hydrolysis; and group D is determined from other viridans streptococci by bile solubility and optochin sensitivity. Anti-streptococcal antibody titers distinguish acute glomerulonephritis and acute rheumatic fever. Acute rheumatic fever is also detected clinically.
Streptococci Testing Market Dynamics
The increasing prevalence of streptococci infection illness is driving market revenue expansion. According to research by the London School of Hygiene and Tropical Medicine, at least 147,000 stillbirths and infant fatalities are expected each year out of 410,000 group B streptococcus instances. Africa bore the greatest weight, accounting for 54% of projected cases and 65% of stillbirths and infant fatalities. The worldwide streptococcus infection market revenue could be driven by a rise in the prevalence of group B streptococcus infections and the rate of new infections. There is a growing demand for rapid diagnostic tests for streptococcal infections as they enable quick and accurate diagnosis. Rapid diagnostic tests are also cost-effective and require less infrastructure and equipment, driving their adoption in healthcare settings. The growth of healthcare infrastructure and expenditure in developing countries is expected to drive the demand for streptococci testing. Increasing access to healthcare facilities and rising awareness about the importance of streptococci testing are also expected to contribute to market revenue growth.
However, despite the increasing incidence of streptococcal infections, many people are unaware of the importance of streptococci testing. Lack of awareness among the general population about the availability and benefits of streptococci testing can restrain the market revenue growth. Some streptococci diagnostic tests can be expensive, limiting their adoption, particularly in low-income countries. The high cost of testing can also be a barrier for patients who cannot afford the tests. Besides, alternative diagnostic methods for streptococcal infections exist, such as clinical examination and culture-based tests. These alternative methods can be less expensive and more readily available, which can limit the adoption of streptococci diagnostic tests.
Streptococci Testing Market Ecosystem
The global Streptococci testing market is analyzed from four perspectives by test type, end user, and region.
Streptococci Testing Market by Test Type
[6786]
The global Streptococci testing market is segmented based on test type into rapid antigen testing, molecular, and throat culture.
The rapid antigen testing segment is expected to dominate the market with the largest revenue share during the forecast period. A swab sample from the throat of an infected patient is tested for antigens using a rapid antigen test. This test can identify strep bacteria in the throat in minutes by searching for substances (antigens). A quick strep test (RST) can help a doctor decide whether to prescribe medication to someone with pharyngitis, a prevalent throat illness. RSTs also support public health. In addition to causing unwanted side effects in the person, it is believed that improper antibiotic use contributes to the formation of drug-resistant types of bacteria. RSTs may help restrict antibiotic use in viral diseases by assisting in identifying bacterial infections. However, the rapid test cannot identify the presence of Group C and G bacteria, which can also cause streptococcal pharyngitis. When a quick strep test has a positive impact, therapy with suitable medications is initiated to avoid long-term harm and recurrence.
The most common technique is throat culture, but it has a comparatively long turnaround time (TAT) of 1-2 days. TAT for RADTs is greatly reduced and can be performed in low-resource or point-of-care environments. However, compared to the pharynx culture technique, RADTs have insufficient sensitivity, ranging between 70% and 90%. Children with clear GAS RADT findings should be retested for S. pyogenes by a throat culture, according to the American Academy of Pediatrics (AAP). Nucleic acid amplification tests (NAATs), such as real-time polymerase chain reaction (PCR), have recently been introduced to identify GAS infections due to their better sensitivity compared to RADTs. However, NAAT TATs are still considerably lengthier than RADTs and are confined to specialized labs due to the need for sophisticated instrumentation.
Streptococci Testing Market by End User
Based on end-user, the global Streptococci testing market is segmented into hospital laboratories, diagnostic laboratories, reference laboratories & others.
Hospital laboratories account for the largest revenue share of the market during the forecast period. Rapid antigen detection assays should be used in hospitals only when antibiotics begin a problem. Antibiotics should be used with care for pharyngitis because they do not delay healing or increase the chance of S pyogenes infections. Sore throats and pharyngitis account for more than 2% and 5% of all ambulatory primary care appointments in adults and children, respectively. This disease is characterized by throat, nasopharynx, and tonsillar tissue inflammation. The frequency season rises in late winter and early spring. Most cases are caused by viral illnesses, with bacterial and fungal diseases accounting for the remaining 20%.
Streptococci Testing Market by Region
Based on region, the global Streptococci testing market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America is expected to expand rapidly in terms of the revenue share of the global streptococci market during the forecast period. This sizable revenue share is attributed to the growing developments in the healthcare sector due to increased R&D efforts in this business. The growing number of steps different research institutes and organizations take to improve medical facilities and services fuel market revenue growth. The Centers for Disease Control and Prevention, a renowned public health institute in the United States, funded many healthcare projects in the region through funding. Additionally, the growing number of bacterial infections and the increasing demand for better diagnostics and preventive measures have resulted in technical developments in medical companies.
Asia Pacific is expected to have the highest revenue CAGR during the forecast period. The bacterial infection Group A streptococcus (GAS) pharyngitis, also known as strep throat, attacks the back of the neck, including the tonsils. It is more prevalent in newborns and the elderly and usually occurs after the winter season. The infection is characterized by fever, sore tongue, stomach pain, nausea, vomiting, red eyes, and diarrhea. High-traffic places such as schools and military institutions are expected to experience the greatest transmission. The usual diagnostic includes a throat culture with improved sensitivity and a rapid strep test, which produces findings rapidly.
Competitive Landscape of the Global Streptococci Testing Market
The prominent market players in the global Streptococci testing market include:
Strategic Development in Streptococci Testing Market
Streptococci are spherical organisms that develop in chains due to imperfect cell separation after mitosis. Streptococci were originally categorized according to the illness they produced; however, because of advancements in diagnostics and the availability of modern molecular methods, many shifts in the taxonomy of the Streptococcus genus have occurred in the last decade.
Asia Pacific is the key growth region in the global Streptococci testing market.
The rapid test segment leads the global Streptococci testing market.
The major players operating in the global Streptococci testing market include Abbott, Beckman Coulter Inc., F. Hoffmann-La Roche Ltd., and others.
Antibiotics segment are currently the only therapy choices for streptococcus infection, and many pharmaceutical companies are working to create non-antibiotic alternatives. Developing a new class of medicines will provide many chances for major players to build, but it will also necessitate significant expenditures in R&D efforts for innovative treatments. The considerably expensive investment requirements could hinder market revenue growth.
*Insights on financial performance are subject to the availability of information in the public domain